TNDM
TANDEM DIABETES CARE INC
NASDAQ · Healthcare · Medical - Devices · US
$19.11
−3.44%Year over year
Reported trailing growth
- Revenue
- -7.1%
- EBITDA
- +80.4%
- EBIT
- +78.4%
- EPS
- +69.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +12.9%
- EBITDA
- +199.8%
- EPS
- +104.0%
Three-year CAGR
- Revenue
- +8.2%
- EBITDA
- —
- EBIT
- +21.2%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026